By binding RANKL with high affinity, which of the following drug reduces bone resorption
By binding to RANKL,denosumab inhibitsRANKL from activating its only receptor RANKon the surface of osteoclasts and their precursors. Prevention of RANKL-RANKinteraction inhibits osteoclast formation, function, and survival; thereby decreasing bone resorption and interrupting cancer-induced bone destruction Ref essentials of pharmacology, k. D tripati 5e
Alemtuzumab
Palivizumab
Daclizumab
Denosumab
General pharmacology